Quoth Wikipedia ever more: Linagliptin (INN, previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2. Once-daily linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type 2 diabetes. It is being marketed by Boehringer Ingelheim and Lilly. Linagliptin may cause severe joint pain.
More Images from
Linagliptin free icon was designed by AdamStanislav for icons Png and presented to its users.
AdamStanislav
2/7/2018